Sélectionner la langue
Mesothelin
Mesothelin Informations sur la molécule
| Nom anglais | Mesothelin | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 45 | Alias de la cible | Pre-pro-megakaryocyte-potentiating factor，Mesothelin，MSLN，CAK1 Antigen，MPF，Soluble MPF Mesothelin Related Protein，Megakaryocyte Potentiating Factor，SMRP，CAK1 |
| Phase de R&D la plus avancée | Phase 2 Clinical | ||
| Nom anglais | Mesothelin |
| Alias de la cible | Pre-pro-megakaryocyte-potentiating factor，Mesothelin，MSLN，CAK1 Antigen，MPF，Soluble MPF Mesothelin Related Protein，Megakaryocyte Potentiating Factor，SMRP，CAK1 |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 45 |
| Phase de R&D la plus avancée | Phase 2 Clinical |
Mesothelin Liste de produits
- Attribut
Protein (27)Beads (1)Cell Grade Beads (1)Cell (2)Kits (1)
- Bibliothèque de produits
En ligne (32)
- Espèces
Human (27)Mouse (3)Cynomolgus (1)Rat (1)
- Étiquette
His Tag (16)Fc Tag (7)His Tag & Avi Tag (3)Fc Tag & Avi Tag (1)- (5)
- Marqueur
Unconjugated (9)Biotin-labeled (6)FITC Labeled (4)GFP Fusion (1)PE Labeled (2)- (5)APC Labeled (2)AF555 Labeled (1)AF647 Labeled (1)AF488 Labeled (1)
Ajouter au panier
Quantité totale32
- 1
- 2
- 3
- 4
MesothelinContexte de la molécule
Mesothelin (MSLN) is also known as CAK1 antigen, Pre-pro-megakaryocyte-potentiating factor, which belongs to the mesothelin family. Mesothelin / MSLN can be proteolytically cleaved into the following two chains by a furin-like convertase: Megakaryocyte-potentiating factor (MPF) and the cleaved form of mesothelin. Both MPF and the cleaved form of mesothelin are N-glycosylated. Mesothelin / MSLN can interacts with MUC16. The membrane-anchored forms of MSLN may play a role in cellular adhesion. MPF potentiates megakaryocyte colony formation in vitro.
MesothelinAlias de la molécule
MSLN,Mesothelin,MPF
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| RC-88 | RC-88 | Phase 2 Clinical | RemeGen Co Ltd | Solid tumours; Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| iCasp9M28z | iCasp9M28z | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Pleural Diseases; Mesothelioma; Breast Neoplasms; Lung Neoplasms; Neoplasm Metastasis | Details |
| Anetumab ravtansine | BAY-94-9343; BAY-94-9343-SPDB-DM4; Anti-mesothelin antibody-drug conjugate BAY 94-9343 | Phase 2 Clinical | Bayer AG, Morphosys Ag | Solid tumours; Ovarian Neoplasms; Cystadenocarcinoma, Serous; Neoplasms; Pancreatic Neoplasms; Mesothelioma; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Endometrioid | Details |
| Gavocabtagene autoleucel | TC-210 | Phase 2 Clinical | Tcr2 Therapeutics Inc | Ovarian Neoplasms; Mesothelioma; Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| LMB-100 | LMB-100; RG-7787; RO-6927005 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Carcinoma; Neoplasms, Mesothelial; Adenocarcinoma of Lung; Pancreatic Neoplasms; Neoplasms; Mesothelioma; Cholangiocarcinoma; Lung Neoplasms; Pleural Effusion, Malignant; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| TCR-like CAR-T Cell Therapy(Zhongda Hospital Southeast University) | Phase 2 Clinical | Zhongda Hospital Southeast University | Ovarian Neoplasms | Details | |
| CD40 ligand expressing MSLN-CAR T cells | Phase 2 Clinical | Pla General Hospital | Solid tumours | Details | |
| A2B-694 | A2B-694; A2B694 | Phase 2 Clinical | A2 Biotherapeutics Inc | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Rectal Neoplasms; Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Mesothelioma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| RNA-Meso-CIR-T | RNA-Meso-CIR-T | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Mesothelioma | Details |
| CART-meso | CART-meso | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Ovarian Neoplasms; Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Mesothelioma; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| anti-MESO CAR-T cells (Zhejiang University) | UCLM802; UCLM-802 | Phase 1 Clinical | Zhejiang University, Hrain Biotechnology Co Ltd | Ovarian Neoplasms; Solid tumours | Details |
| Anti-mesothelin thorium-227 labeled antibody chelator conjugate | BAY-2287411 | Phase 1 Clinical | Bayer AG | Ovarian Neoplasms; Mesothelioma; Carcinoma, Pancreatic Ductal | Details |
| GC-503 | GC-503 | Phase 1 Clinical | Solid tumours | Details | |
| iCasp9M28z T cells | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Mesothelioma; Breast Neoplasms; Lung Neoplasms | Details | |
| anti-mesothelin CAR T-cell therapy (Chinese PLA General Hospital) | Phase 1 Clinical | Pla General Hospital | Solid tumours | Details | |
| HPN-536 | HPN-536 | Phase 1 Clinical | Harpoon Therapeutics | Neoplasms | Details |
| AB-1015 | AB-1015 | Phase 1 Clinical | Arsenal Biosciences Inc | Ovarian Neoplasms; Carcinoma, Ovarian Epithelial | Details |
| SynKIR-110 | SynKIR™-110; SynKIR-meso | Phase 1 Clinical | Verismo Therapeutics Inc | Ovarian Neoplasms; Mesothelioma; Cholangiocarcinoma | Details |
| KT-032 | KT-032 | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Ovarian Neoplasms; Solid tumours; Pancreatic Neoplasms; Mesothelioma | Details |
| NI-1801 | NI-1801 | Phase 1 Clinical | Light Chain Bioscience Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung | Details |
| Universal Chimeric Antigen Receptor T-Cell Immunotherapy(Calmhome Cell and Gene Engineering Institute) | CHT102; CHT-102 | Phase 1 Clinical | Tianjin Medical University Cancer Institute And Hospital | Solid tumours; Pancreatic Neoplasms | Details |
| Mesothelin x CD3 Bispecific Antibody(Integral Molecular) | LNK-101; CT-95; LNK101 | Phase 1 Clinical | Integral Molecular Inc | Solid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Mesothelioma; Cholangiocarcinoma; Neoplasm Metastasis | Details |
| JNJ-79032421 | JNJ-79032421; JNJ-2421 | Phase 1 Clinical | Janssen Research & Development Llc | Solid tumours | Details |
| YL-215 | YL215; YL-215 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | Details |
| GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Mesothelioma; Lung Neoplasms | Details | |
| AMG 305 | AMG-305; AMG 305 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| Mesothelin-CAR-T Cells (Fapon Biopharma) | Phase 1 Clinical | Fapon Biotech Inc | Pancreatic Neoplasms | Details | |
| UCMYM-802 | UCMYM802; UCMYM-802 | Phase 1 Clinical | Shanghai Youti zjisheng Biomedicine Co Ltd | Solid tumours; Ovarian Neoplasms; Rectal Neoplasms; Pancreatic Neoplasms; Mesothelioma; Breast Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms | Details |
| HBM-9033 | HBM-9033; HBM9033; SGN-MesoC2 | Phase 1 Clinical | Nona Biosciences | Solid tumours; Ovarian Neoplasms; Pancreatic Neoplasms; Mesothelioma; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-mesothelin CAR T cell therapy (UTC Therapeutics Inc) | Phase 1 Clinical | UTC Therapeutics Inc | Solid tumours | Details | |
| ZW-171 | ZW-171 | Phase 1 Clinical | Zymeworks Inc | Solid tumours; Neoplasms | Details |
| LD013 CAR T-cell therapy (Nanjing Landun Biotechnology) | LD013; LD-013 | Phase 1 Clinical | Nanjing Landun Biotechnology Co Ltd | Ovarian Neoplasms; Solid tumours | Details |
| Ori-C-613 | Ori-C-613; OriC-613; Ori-C613 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Solid tumours | Details |
| RD-138 | RD-138 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Multiple Myeloma | Details |
| RD-133 | RD133 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Solid tumours; Neoplasms | Details |
| PM-3006 | PM-3006 | Phase 1 Clinical | Details | ||
| Autologous Mesothelin-specific TCR-T Cell Therapy (Lonza Walkersville) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal | Details | |
| Anti-mesothelin CAR-NK cell therapy(Guojianchengnuo) | ALF-101 | Phase 1 Clinical | Guojianchengnuo Biotechnology (Beijing) Co Ltd | Carcinoma, Ovarian Epithelial | Details |
| Inezetamab | AMG-994 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| ATA-2271 | ATA-2271 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Atara Biotherapeutics Inc, Bayer AG | Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Mesothelioma; Breast Neoplasms; Peritoneal Neoplasms; Esophageal adenocarcinoma; Diabetes Mellitus; Adenocarcinoma | Details |
| αPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd) | BZDS1901; BZDS-1901; BZD1901 | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Ovarian Neoplasms; Solid tumours; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| KD-021 | KD-021 | Phase 1 Clinical | Nanjing Kaedi Biotechnology Co Ltd | Neoplasms | Details |
| anti-mesothelin CAR T-cell therapy (Shenzhen BinDeBio) | Clinical | Shenzhen Bindebio Ltd | Pancreatic Neoplasms | Details | |
| Anti-mesothelin CAR-T (Pregene) | Clinical | Pregene (Shenzhen) Biotechnology Co Ltd | Hydrothorax | Details |
Avis sur les produits
B***a2023-07-11
0Mettre un likeThis is one of the only conjugated mesothelin proteins available on the market! It has great specificity for flow cytometry staining, this has been a game changer for us to measure human mesothelin present in our samples with an easy and quick one-step staining method. This is a great quality product and we will be ordering so many more in the future!
- Informations sur la molécule
- Liste de produits
- Avis sur les produits
- Informations sur les médicaments cliniques
Partager vers :
Message en ligne
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved